Josh Drago (@joshdragomd) 's Twitter Profile
Josh Drago

@joshdragomd

Assistant Attending Physician at Memorial Sloan Kettering Cancer Center. Breast Cancer Specialist. Tweets are my own.

ID: 926576426878427137

calendar_today03-11-2017 22:26:49

34 Tweet

238 Followers

289 Following

Nature Medicine (@naturemedicine) 's Twitter Profile Photo

A new paper by authors at @sloan_kettering shows clonal hematopoiesis is a major source of somatic mutations detected in liquid biopsies of #Cancer patients nature.com/articles/s4159… #PrecisionMedicine #genomics #CancerScreenWeek

A new paper by authors at @sloan_kettering shows clonal hematopoiesis is a major source of somatic mutations detected in liquid biopsies of #Cancer patients nature.com/articles/s4159… #PrecisionMedicine #genomics #CancerScreenWeek
Josh Drago (@joshdragomd) 's Twitter Profile Photo

Extremely compelling phase 2 results of trastuzumab deruxtecan, second generation HER2 ADC in MBC. Proud of #MSKCC mentor Shanu Modi! Lots of potential for this agent. #SABCS2019 @sloan_kettering

Aditya Bardia, MD (@dradityabardia) 's Twitter Profile Photo

Tucatinib (HER2 TKI), Trastuzumab, and Capecitabine Triplet associated with improved PFS in HER2+ MBC (33.1% vs 12.3% at 1-year; HR:0.54), including pts with brain mets (PFS at 1 yr - 24% vs 0%). NEJM nejm.org/doi/full/10.10…

Catherine Ormerod (@cormerod) 's Twitter Profile Photo

Marina Kaplan w/her research on patient solutions to increase clinical trial participation #SABCS19. An epidemiologist, 2019 ⁦Living Beyond Breast Cancer⁩ Hear My Voice advocate,& TNBC patient, Marina is helping to address the low rates of clinical trial enrollment. #bcsm #metastaticBC

Marina Kaplan w/her research on patient solutions to increase clinical trial participation #SABCS19. An epidemiologist, 2019 ⁦<a href="/LivingBeyondBC/">Living Beyond Breast Cancer</a>⁩ Hear My Voice advocate,&amp; TNBC patient, Marina is helping to address the low rates of clinical trial enrollment. #bcsm #metastaticBC
Josh Drago (@joshdragomd) 's Twitter Profile Photo

Thank you #GRASPcancer for all of the incredible work you do! Speaking with you all was the highlight of my morning for sure.

Tatiana Prowell, MD (@tmprowell) 's Twitter Profile Photo

FDA granted accelerated approval today to HER-2-targeted ADC, DS-8201a, for tx of #HER2pos #MBC. Happy holidays #bcsm. Full info here: fda.gov/news-events/pr…

Josh Drago (@joshdragomd) 's Twitter Profile Photo

Thanks Gʀᴇɢᴏʀʏ Rɪᴇʟʏ! We think this is a really important topic, and hope this work leads to further dialogue about drug safety in oncology. Glad you enjoyed the reference 😊

soria (@jsoriamd) 's Twitter Profile Photo

Antibody–drug conjugates (smart chemotherapies) are becoming key new players in #cancer therapy doi.org/10.1038/s41571…

Antibody–drug conjugates (smart chemotherapies) are becoming key new players in #cancer therapy 
doi.org/10.1038/s41571…
Marie Will, MD, PhD (@mariewill_mdphd) 's Twitter Profile Photo

Sharing this new Nature Reviews Cancer article on the evolution of the estrogen receptor as a therapeutic target for breast cancer, authored by me, Jackson Liang, Ciara Metcalfe, and Sarat Chandarlapaty! nature.com/articles/s4156…

Rei Kudo_MDPhD (@reik0110) 's Twitter Profile Photo

Delighted to share our research Cancer Cell Memorial Sloan Kettering Cancer Center ! We explore the mechanisms behind variable #BreastCancer responses to CDK4/6 inhibitors. TP53 mutation is linked to lack of long-term disease control. cell.com/cancer-cell/fu…

Avantika Gupta (@avangupta) 's Twitter Profile Photo

T-DXd has remarkable activity in HER2+ cancers but benefits vary even in HER2-high tumors. Our latest Cell Reports Medicine study reveals that EGFR suppresses T-DXd's antitumor activity & presents a rapidly translatable combo strategy to overcome this resistance. 🧵cell.com/cell-reports-m…